Asset Details
Do you wish to reserve the book?
Impact of genetic variants on major bleeding after percutaneous coronary intervention based on a prospective multicenter registry
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Impact of genetic variants on major bleeding after percutaneous coronary intervention based on a prospective multicenter registry
Do you wish to request the book?
Impact of genetic variants on major bleeding after percutaneous coronary intervention based on a prospective multicenter registry
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Impact of genetic variants on major bleeding after percutaneous coronary intervention based on a prospective multicenter registry
2021
Overview
Although dual antiplatelet therapy is essential for patients who undergo percutaneous coronary interventions, the risk of bleeding remains an unsolved problem, and there is limited information on the potential relationship between genetic variants and major bleeding. We analyzed the correlations between four major single nucleotide polymorphisms (CYP2C19, ABCB1, PON1, and P2Y12 G52T polymorphisms) and clinical outcomes in 4489 patients from a prospective multicenter registry. The primary endpoint was major bleeding, defined as a Bleeding Academic Research Consortium ≥ 3 bleeding event. The allelic frequencies of ABCB1, PON1, and both individual and combined CYP2C19 variants did not differ significantly between patient groups with and without major bleeding. However, the allelic frequency of the P2Y12 variant differed significantly between the two groups. Focusing on the P2Y12 G52T variant, patients in the TT group had a significantly higher rate of major bleeding (6.4%; adjusted hazard ratio [HR] 2.51; 95% confidence interval [CI] 1.08–5.84; p = 0.033) than patients in the other groups (GG [2.9%] or GT [1.9%]). Therefore, the TT variant of the P2Y12 G52T polymorphism may be an independent predictor of major bleeding.
Trial registration
: NCT02707445 (
https://clinicaltrials.gov/ct2/show/NCT02707445?term=02707445&draw=2&rank=1
).
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Anemia
/ Bleeding
/ Diabetes
/ Genes
/ Humanities and Social Sciences
/ Medicine
/ Patients
/ Science
/ Single-nucleotide polymorphism
/ Stents
